TBPH - שווי שוק לנפח מכירות Theravance Biopharma Inc

Risks for Theravance Biopharma (TBPH) are linked to a dependence on Trelegy payments and regulatory pressure. This chart in the GURU.Markets terminal illustrates the revenue multiple level, which currently stands at 8.50. Business stability is supported by passive income from respiratory drug patents, while the environmental profile meets international standards through production outsourcing.
פילוחים אנליטיים של חברת Theravance Corp (TBPH)

The P/S multiple reflects the market value of a business relative to its generated revenue, allowing an investor to assess the degree of overpayment for an asset regardless of current profitability. By analyzing the price-to-sales ratio, one can evaluate the monetization efficiency of Theravance Biopharma (TBPH) patent rights, where stable royalties from the GSK partnership create a predictable cash flow without operational distribution costs.